scholarly journals Analysis of the Immune Responses in the Ileum of Gnotobiotic Pigs Infected with the Recombinant GII.p12_GII.3 Human Norovirus by mRNA Sequencing

Viruses ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 92
Author(s):  
Byung-Joo Park ◽  
Hee-Seop Ahn ◽  
Sang-Hoon Han ◽  
Hyeon-Jeong Go ◽  
Dong-Hwi Kim ◽  
...  

Norovirus genogroup II (NoV GII) induces acute gastrointestinal food-borne illness in humans. Because gnotobiotic pigs can be infected with human norovirus (HuNoV) GII, they are frequently used to analyze the associated pathogenic mechanisms and immune responses, which remain poorly understood. Recently, mRNA sequencing analysis (RNA-Seq) has been used to identify cellular responses to viruses. In this study, we investigated the host immune response and possible mechanisms involved in virus evasion in the ileum of gnotobiotic pigs infected with HuNoV by RNA-Seq. HuNoV was detected in the feces, blood, and tissues of the jejunum, ileum, colon, mesenteric lymph node, and spleen of pigs infected with HuNoV. In analysis of mRNA sequencing, expression of anti-viral protein genes such as OAS1, MX1, and MX2 were largely decreased, whereas type I IFN was increased in pigs infected with HuNoV. In addition, expression of TNF and associated anti-inflammatory cytokine genes such as IL10 was increased in HuNoV-infected pigs. Expression of genes related to natural killer (NK) cell cytotoxicity and CD8+ T cell exhaustion was increased, whereas that of MHC class I genes was decreased. Expression profiles of selected genes were further confirmed by qRT-PCR and Western blot. These results suggest that infection with HuNoV induces NK cell-mediated cytotoxicity but suppresses type I IFN- and CD8+ T cell-mediated antiviral responses.

PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e40865 ◽  
Author(s):  
Selina Jessica Keppler ◽  
Kerstin Rosenits ◽  
Tamara Koegl ◽  
Smiljka Vucikuja ◽  
Peter Aichele

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi181-vi181
Author(s):  
Yuanfan Yang ◽  
Michael Brown ◽  
Kevin Stevenson ◽  
Giselle lopez ◽  
Reb Kornahrens ◽  
...  

Abstract Immunotherapy with polio:rhinovirus recombinant (PVSRIPO) has shown evidence of efficacy in a phase I clinical trial for recurrent GBM, resulting in durable radiographic responses and 21% long-term survival at 36 months. Ongoing research aims to enhance the clinical response rate by resolving the mechanisms of action and therapy resistance in vivo, thereby devising more effective therapies. Mouse glioma (CT2A) cells were intracranially implanted (day 0) in transgenic mice carrying poliovirus receptor CD155, and treated with intratumor PVSRIPO (5×105 pfu; day 6) to dissect early and late events following therapy. A blinded pathological review of 45 post-treatment tumors was performed. On day 8, a histological response, featured by tumor dissociation and shrinkage, with inflammation and microglia enrichment in the treated hemisphere, was common in PVSRIPO group (6/7) compared to controls (0/4). However, the response rate fell over time (7/12 on day 12; 1/7 on day 15) and the therapy was overcome by aggressive tumor regrowth. RNAseq was performed and Gene Set Enrichment Analysis of the tumor microenvironment revealed an acute type-I interferon (IFN)-related inflammation, correlating with the histological findings of profound proinflammatory engagement of microglia (Iba1+) widespread in the treated hemisphere. Microglia proliferation (Ki67+) was observed in the treated hemisphere, likely resulting from PVSRIPO infection, in CT2A and B16 intracranial models. This suggests an association of adaptive antitumor immunity—elicited by immediate intratumor type-I IFN-dominant inflammation—with tumor regression. Thus, buttressing type-I IFN directed antitumor CD8+T cell immunity, e.g. with blockade of the PD1:PD-L1 immune checkpoint, might contribute to tumor remission. Indeed, combination therapy with αPD-L1 antibody in the CT2A model showed longer median survival and higher long-term remission rate compared to monotherapy alone; CD8 T cell depletion can completely abrogate this efficacy with this therapy combination, confirming the role of anti-tumor immunity in this approach.


2009 ◽  
Vol 182 (5) ◽  
pp. 2786-2794 ◽  
Author(s):  
Zhengguo Xiao ◽  
Kerry A. Casey ◽  
Stephen C. Jameson ◽  
Julie M. Curtsinger ◽  
Matthew F. Mescher

2011 ◽  
Vol 186 (4) ◽  
pp. 2106-2116 ◽  
Author(s):  
Marta Catalfamo ◽  
Christopher Wilhelm ◽  
Lueng Tcheung ◽  
Michael Proschan ◽  
Travis Friesen ◽  
...  

2021 ◽  
Vol 7 (36) ◽  
Author(s):  
Yoon-Chul Kye ◽  
Gil-Woo Lee ◽  
Sung-Woo Lee ◽  
Young-Jun Ju ◽  
Hee-Ok Kim ◽  
...  

2016 ◽  
Vol 29 (2) ◽  
pp. 112-127 ◽  
Author(s):  
Ke Wen ◽  
Tammy Bui ◽  
Mariah Weiss ◽  
Guohua Li ◽  
Jacob Kocher ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document